The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predictors are poorly known. It was the study objective to evaluate the impact of baseline lupus anticoagulant assays, IgG anticardiolipin (aCL), plasma fibrinogen (FNG) and von Willebrand factor (VWF), platelets (PLT) and of genetic polymorphisms of methylenetetrahydrofolate reductase C677T, of prothrombin G20210A and of paraoxonase-1 Q192R on mortality in primary APS (PAPS). Cohort study on 77 thrombotic PAPS and 33 asymptomatic carriers of aPL (PCaPL) seen from 1989 to 2015 and persistently positive for aPL as per annual review. At baseline all participants were tested twice for the ratios of kaolin clotting time (KCTr), activated partial thromb...
OBJECTIVES: aPL are present in between 20 and 30% of patients with SLE. They can cause vascular even...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
The natural history of antiphospholipid antibodies (aPL) carriers is not well-established. The objec...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objective: We aimed to identify features that allow differentiation of primary antiphospholipid synd...
OBJECTIVES: To determine whether early damage and its kinetics measured by the Damage Index for Anti...
Background and Purpose - Because thromboembolic events are frequently observed in primary antiphosph...
The aim of this study was to present our diagnostic and therapeutic experience with antiphospholipid...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
IntroductionAntiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (ar...
OBJECTIVES: aPL are present in between 20 and 30% of patients with SLE. They can cause vascular even...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
The natural history of antiphospholipid antibodies (aPL) carriers is not well-established. The objec...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objective: We aimed to identify features that allow differentiation of primary antiphospholipid synd...
OBJECTIVES: To determine whether early damage and its kinetics measured by the Damage Index for Anti...
Background and Purpose - Because thromboembolic events are frequently observed in primary antiphosph...
The aim of this study was to present our diagnostic and therapeutic experience with antiphospholipid...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
IntroductionAntiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (ar...
OBJECTIVES: aPL are present in between 20 and 30% of patients with SLE. They can cause vascular even...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...